Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
May 09, 2017 20:05 pm UTC| Business
MENLO PARK, Calif., May 09, 2017 -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate principal amount of Convertible Senior...
Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
May 09, 2017 20:05 pm UTC| Business
MENLO PARK, Calif., May 09, 2017 -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate principal amount of Convertible Senior...
Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
May 09, 2017 20:05 pm UTC| Business
MENLO PARK, Calif., May 09, 2017 -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate principal amount of Convertible Senior...
Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
May 09, 2017 20:05 pm UTC| Business
MENLO PARK, Calif., May 09, 2017 -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate principal amount of Convertible Senior...
Rockwell Medical Reports First Quarter Results
May 09, 2017 20:05 pm UTC| Business
WIXOM, Mich., May 09, 2017 -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the...
Rockwell Medical Reports First Quarter Results
May 09, 2017 20:05 pm UTC| Business
WIXOM, Mich., May 09, 2017 -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the...
REGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights
May 09, 2017 20:05 pm UTC| Business
On track to initiate dosing of patients in RGX-314 Phase I trial for wet AMD by mid-2017 and continuing enrollment of patients in RGX-501 Phase I/II trial for HoFHInterim trial updates for RGX-314 and RGX-501 anticipated...